HCV protease inhibitors bring new options for patients
- Two drugs approved for chronic hepatitis C infection. Traynor, Kate // American Journal of Health-System Pharmacy;7/1/2011, Vol. 68 Issue 13, p1176
The article reports on the FDA's approval of two hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir, marketed as Victrelis by Merck and telaprevir, marketed as Incivek by Vertex Pharmaceuticals, for the treatment of adults with chronic HCV infection caused by genotype 1 viruses....
- Simeprevir: First Global Approval. Vaidya, Asha; Perry, Caroline M. // Drugs;Dec2013, Vol. 73 Issue 18, p2093
Simeprevir (Sovriad TM) is a new direct-acting antiviral drug and a second-generation small-molecule NS3/4A serine protease inhibitor developed by Janssen and Medivir for the oral treatment of adults with genotype 1 and/or genotype 4 chronic hepatitis C virus (HCV) infection (chronic hepatitis...
- Hepatitis C treatment options improving. // Mayo Clinic Health Letter;Jan2013, Vol. 31 Issue 1, p4
The article reports that treatment with newly approved drugs, telaprevir and boceprevir, protease inhibitors, may be more effective for older adults with hepatitis C virus, than treatment with the standard therapies.
- Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection. Rheem, Justin; Sundaram, Vinay; Saab, Sammy // Gastroenterology & Hepatology;May2015, Vol. 11 Issue 5, p294
The emergence of direct-acting antiviral (DAA) agents has revolutionized the treatment schema for hepatitis C virus (HCV) infection. From cure rates to tolerability, DAA agents have shown outstanding profiles compared with the prior therapy of pegylated interferon with ribavirin. However, the...
- New molecular entities/biologics. // Formulary;Aug2006, Vol. 41 Issue 8, p362
The article provides information related to several drug approvals by the U.S. Food and Drug Administration. A monoclonal antibody called Ranibizumab was approved for the treatment of age-related macular degeneration. An approval was granted to Darunavir, a protease inhibitor used for the...
- Vorapaxar: First Global Approval. Poole, Raewyn; Elkinson, Shelley // Drugs;Jul2014, Vol. 74 Issue 10, p1153
Vorapaxar [Zontivity (US)], an orally active protease-activated receptor-1 (PAR-1) receptor antagonist, has been developed by Merck & Co for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). Vorapaxar...
- Two new approvals bring hope to patients with hepatitis C. TANZI, MARIA G. // Pharmacy Today;Oct2015, p46
The article discusses the approval of two drugs Daclatasvir and a combination of Ombitasvir, paritaprevir, and ritonavir by the Food and Drug Association (FDA) and notes that these drugs helps in treating hepatitis C.
- FDA approves two hepatitis C treatments. // Infectious Disease News;Dec2013, Vol. 26 Issue 12, p7
The article reports that the U.S. Food and Drug Administration (FDA) has approved the once-daily oral nucleotide analog sofosbuvir and simeprevir for the treatment of hepatitis C virus infection as of December 2013.
- Two new hep C meds approved. Highleyman, Liz // Bay Area Reporter;6/16/2011, Vol. 41 Issue 24, p1
The article reports on the approval of the first two antiviral drugs for the treatment of chronic hepatitis C, such as boceprevir (Victrealis) from Merck & Co. Inc. and telaprevir (Incivek) from Vertex Pharmaceuticals Inc., by the U.S. Food and Drug Administration.